Abstract: Memory management processes allocate and recycle pages of replication data pointer (RDP) metadata space in shared memory. When the RDP page currently allocated to an IO thread becomes full, that RDP page is released, and a new RDP page is allocated to the IO thread. The released page eventually becomes fragmented and is added to a list of RDP pages that are ranked based on partial fullness. An IO thread that needs a new RDP page is allocated a mostly empty RDP page from the ranked list, if such a page is available. Otherwise, a new completely empty RDP page is allocated to the IO thread. Use of the ranked lists reduces latency associated with allocation of new RDP pages. Contention between IO threads for RDP metadata space is reduced because each IO thread has exclusive rights to the free RDP metadata space in its currently allocated page.

Abstract: The present invention relates to lipid compounds that can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and/or analogues thereof, and/or polymer conjugated lipids to form lipid nanoparticles for delivery of therapeutic and/or prophylactic agents. In some examples, lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and/or antisense RNA. Methods of using these lipid nanoparticles to treat and/or prevent various diseases are also provided. In one embodiment, a compound having the structure of formula (I) below is provided: or a salt or isomer thereof or an N-oxide thereof, wherein RI is as defined herein. Pharmaceutical compositions comprising one or more compounds of the aforementioned structural formula (I) and therapeutic and/or prophylactic agents are also provided.

Abstract: A pharmaceutical composition containing a deuterated cyano compound, isomer, prodrug, solvate, or pharmaceutically acceptable salt thereof, and a deuterated cytidine derivative, isomer, prodrug, solvate, or pharmaceutically acceptable salt thereof, and its use as an antiviral.

Abstract: The invention provides an etching method of a semiconductor structure, which comprises providing a substrate with a gate structure, an oxide layer and a first nitride layer beside the gate structure, and performing an etching step to remove the first nitride layer and keep the oxide layer, wherein in the etching step, the etching selectivity ratio of the etched nitride material to the etched oxide material is greater than 300.

Abstract: Deuterated cyano compounds useful as a 3CL protease inhibitor, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of treating a viral infection in a human by administering the compounds.

Abstract: The invention relates to lipid compounds that can be used alone or in combination with other lipid components, such as neutral lipids, charged lipids, steroids, and polymer conjugated lipids to form lipid nanoparticles for delivery of therapeutic and/or prophylactic agents; pharmaceutical compositions containing the lipid nanoparticles; and methods of using the lipid nanoparticles to treat or prevent diseases.

Abstract: A display panel includes a substrate, a plurality of data lines, at least one repair line, at least one compensation line and a data driver. The repair line is arranged on the substrate and overlapped with at least part of the plurality of data lines, for connecting with a broken data line when the broken data line with a breakpoint exists in the plurality of data lines, to repair the broken data line. Each compensation line is connected to the repair line through a resistor. The data driver includes a plurality of first output channels connected to the plurality of data lines, at least one second output channel connected to an end of the repair line away from the resistor and at least one third output channel connected to an end of the compensation line away from the resistor.

Abstract: Memory management processes allocate and recycle pages of replication data pointer (RDP) metadata space in shared memory. When the RDP page currently allocated to an IO thread becomes full, that RDP page is released, and a new RDP page is allocated to the IO thread. The released page eventually becomes fragmented and is added to a list of RDP pages that are ranked based on partial fullness. An IO thread that needs a new RDP page is allocated a mostly empty RDP page from the ranked list, if such a page is available. Otherwise, a new completely empty RDP page is allocated to the IO thread. Use of the ranked lists reduces latency associated with allocation of new RDP pages. Contention between IO threads for RDP metadata space is reduced because each IO thread has exclusive rights to the free RDP metadata space in its currently allocated page.

Abstract: Direct Image Lookup (DIL) metadata is used to perform differential operation for snapshots and linked targets. Each snapshot contains metadata to store “images” to perform direct lookup of user data for any part of any snapshot in the system. Metadata pages of DIL image data represent sets of tracks of data. Metadata pages of subsequent snapshots for the same sets of tracks are compared, and where there are no changes to a given metadata page for a given set of tracks between subsequent snapshot copies, the differential process is not run on the tracks associated with the metadata page. If a given metadata page associated with a set of tracks has changed between subsequent snapshots, the differential process is used to identify which tracks in the subsequent snapshot contain different data than the corresponding tracks of the previous snapshot. Similar differential processing also is implemented for relinked target devices.

Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) an active substance selected from umeclidinium bromide and vilanterol trifenatate and combinations thereof; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; and (d) a pharmacologically acceptable preservative, and optionally includes a pharmacologically acceptable stabilizer, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.

Abstract: The present application provides a display panel and a driving method of the display panel. The display panel includes an output circuit board having multiple output terminals. The output terminal includes at least two output channels, one of which is electrically connected to one of data lines. At a first moment, a first portion of subpixels in an i-th row receive data signals input from the corresponding data lines. At a second time, a second portion of the sub-pixels in the i-th row excluding the first portion receive data signals input from the corresponding data lines.

Abstract: The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

Abstract: The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

Abstract: The present invention is directed to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) active substances selected from budesonide and olodaterol; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, and (e) a pharmacologically acceptable stabilizer.

Abstract: The disclosure provides a polarizer and a display panel. The polarizer is disposed in the display panel and includes a body layer and a touch control layer disposed on the body layer. The touch control layer includes a plurality of touch sensors. An area of the touch control layer is greater than or equal to an area of the display area of the display panel, and the touch control layer is electrically connected to the touch driver circuit by a wire. In the display panel, a bonding area of the touch control layer and touch units are disposed on a same layer, thereby reducing a non-display area.

Abstract: A liquid crystal display device includes a display panel, a printed circuit board assembly, a chip carrier film structure connected to the display panel and the printed circuit board assembly, a frame, and an electrostatic discharge structure. The electrostatic discharge structure includes a grounding structure disposed on the printed circuit board assembly. A grounding element is electrically connected to a side of the grounding structure of the printed circuit board assembly. A peripheral electrostatic discharge trace is disposed between the frame and the display panel and is connected to the grounding element, and includes a first guiding portion. A voltage regulating element is electrically connected between the grounding structure of the printed circuit board assembly and the first guiding portion of the peripheral electrostatic discharge trace.

Abstract: The present invention relates to a pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: batefenterol or a pharmaceutically acceptable salt thereof, fluticasone furoate, and a pH adjusting agent.